CD8A and non-small cell lung carcinoma: PD-1 was found to be a cell-surface marker to identify PB neoantigen-reactive T cells44, and a recent study showed TCR clonality changes can be observed in PB PD-1+CD8+ T cells in NSCLC patients treated with anti-PD-1 therapy59.